News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article is a Q2 earnings snapshot for Allot Communications. No specific financial details are provided in the current content.
Allot Ltd. reported Q2 2026 financial results that surpassed Wall Street expectations, with non-GAAP earnings per share at $0.09 against an estimated $0.06, and revenue reaching $27.7M, a 15% increase year-over-year. The company's SECaaS division was a significant growth driver, and Allot projects full-year …
Allot Ltd. reported strong Q2 2026 earnings, with non-GAAP EPS of $0.09 significantly beating estimates and revenue increasing by 15% year-over-year to $27.7 million. The company's Security-as-a-Service (SECaaS) segment was a major driver, growing 47% to $9.4 million. Full-year revenue guidance was set between …
Allogene Therapeutics reported a narrower-than-expected loss for Q2 2026, with adjusted EPS of negative $0.13 against a forecast of negative $0.17. Revenue significantly surpassed expectations, driven primarily by clinical advancements rather than financial metrics. The company's ALPHA3 trial in large B-cell lymphoma is progressing …
This article from TradingView discusses the exchange rate effect on BlackRock Capital Allocation Term Trust, traded on Tradegate Exchange under the symbol BD8. The content appears to be a financial data page rather than an analytical article, showing general information about the trust and …
Allogene Therapeutics (NASDAQ: ALLO) reported better-than-expected earnings for the second quarter, beating analyst EPS estimates by $0.04 and significantly exceeding revenue forecasts. The company posted an EPS of $-0.130 on revenue of $4.64M. The stock has shown strong performance, rising 2.750% in the last …
Allogene Therapeutics Inc. reported a Q2 loss of $42.7 million, or 13 cents per share, surpassing Wall Street expectations which had forecast a loss of 16 cents per share. The immuno-oncology company generated $4.5 million in revenue for the period. Shares of Allogene Therapeutics …
REalloys Inc (NASDAQ:ALOY) experienced unusually high options trading volume on Wednesday, with traders purchasing 7,638 put options, a 390% increase from the average. The company's stock traded up by $0.07, reaching $12.82, and has an average rating of "Moderate Buy" from analysts with a …
Unusual put option activity in REalloys Inc. (ALOY) suggests investors might be bullish on the stock ahead of its earnings report next week. Despite concerns about potential future capital raises due to the company's losses, the high premium on out-of-the-money puts expiring on September …
Allogene Therapeutics reported its second-quarter 2026 financial results, highlighting significant progress in its ALPHA3 program for cema-cel in 1L Large B-cell Lymphoma, which received RMAT and Fast Track designations from the FDA. The company also provided an update on its Phase 1 RESOLUTION trial …
BlackRock Capital Allocation Term Trust (NYSE:BCAT) has declared a monthly dividend of $0.2542 per share, payable on August 31st to shareholders of record on August 14th, representing an annualized yield of approximately 19.0%. Shares opened at $16.09, close to its 12-month high, and institutional …
Ascent Industries (ACNT) reported strong Q2 2026 results, with net sales increasing 37.6% to $25.7 million and adjusted EBITDA turning positive at $1.5 million. The growth was driven by broad-based improvements in volume, average selling prices, and the contribution from the Midwest Graphic Sales …
Allot Ltd. reported a significant 15% revenue increase in Q2 2026, reaching $27.7 million, largely due to a 47% rise in Security-as-a-Service revenues. This strong performance, combined with $8.5 million in operating cash flow and a reversal of last year's operating loss, led the …
Allot Ltd. announced strong financial results for the second quarter of 2026, marking its fourth consecutive quarter of double-digit growth with revenues reaching $27.7 million, up 15% year-over-year. The company reported significant growth in Security-as-a-Service (SECaaS) revenues, which increased by 47% year-over-year to $9.4 …
Allot Ltd. (NASDAQ: ALLT) reported a return to profit in Q2 2026, with GAAP net income of $2.6 million compared to a loss a year prior, driven by a 15% year-over-year revenue increase to $27.7 million. The company also raised its full-year 2026 revenue …
Sharemaestro market context Price below Trend Line 52 weeks -7.0%BlackRock Capital Allocation Term Trust (BCAT) recently achieved a new 52-week high, trading at $16.1650 with significant volume. The fund also announced a monthly dividend of $0.2542 per share, representing an 18.9% yield. Institutional ownership of BCAT stands at 36.12%, with several hedge funds …
A moomoo community user expressed their affection for REalloys (ALOY.US) in a short post. The article includes the user's comment, engagement metrics, and disclaimers about the community being for educational purposes. It also features a list of featured tech stocks.
Allogene Therapeutics, Inc. is projected to report a loss of 17 cents per share. This information comes from an earnings preview, indicating an anticipated financial performance for the company. The full article provides more details, accessible through a TradingView subscription.
This article analyzes Guggenheim Active Allocation Fund (NYSE: GUG), highlighting a neutral near-term sentiment that could mitigate mid-term weakness. It identifies an exceptional 13.5:1 risk-reward setup targeting a 3.6% gain against 0.3% risk. The article details three institutional trading strategies (Position, Momentum Breakout, and …
David Eyal Harari, CEO of Allot (NASDAQ: ALLT), sold 29,111 shares of the company's stock, totaling $222,378, according to a recent SEC filing on August 10. Allot's stock was trading up 0.38% at $7.73 at the time of the report. The article also provides …
Allot Ltd. CEO Eyal David Harari sold 29,111 ordinary shares on August 6, 2026, to cover tax withholdings related to restricted share unit vesting. This transaction was disclosed in a Form 4 filed on August 10, 2026.
Allot Ltd.'s CEO, Eyal David Harari, sold 29,111 shares of the company's stock for $222,408.04, reducing his ownership by 2.58%. Despite this insider selling, the company has a "Moderate Buy" consensus rating from analysts with an average price target of $13.62, and its board …
This article provides the "Total debt per share" for BlackRock Capital Allocation Term Trust (NYSE: BCAT) from TradingView. It indicates that the market was closed at the time of viewing and no trades were recorded. The content is primarily a data point rather than …
This article analyzes Blackrock Esg Capital Allocation Term Trust Shs Ben Int (NASDAQ: ECAT) and provides AI-generated trading strategies. It highlights strong near-term sentiment but neutral mid and long-term outlooks, with no resistance levels above the current price, suggesting upside potential. The report details …
Search by ticker symbol or company name and select a result to open its chart.